Anaflat

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Anaflat

What is Anaflat?

Anaflat is an oral medication formulated to address symptoms associated with the accumulation of excess gas in the digestive tract. It is primarily used to relieve physical discomfort, pressure, and bloating caused by gas in the stomach and intestines.

Composition and Mechanism

The active component in Anaflat is simethicone, a substance classified as an anti-foaming agent or surfactant. Unlike medications that reduce gas production through metabolic or enzymatic changes, Anaflat works through a physical process:

  • Surface Tension Alteration: Simethicone changes the surface tension of gas bubbles trapped within the gastrointestinal tract.
  • Coalescence: By reducing surface tension, the medication causes smaller, dispersed gas bubbles to join together into larger bubbles.
  • Elimination: These larger bubbles are more easily passed through the body via natural processes, such as belching or flatulence.

Clinical Applications

Anaflat is utilized in various clinical and everyday contexts to manage gastrointestinal air and gas. Its applications include:

  • Symptomatic Relief: Reducing the sensation of fullness, pressure, and abdominal distension related to gas.
  • Post-Surgical Recovery: Assisting patients who experience gas buildup following abdominal surgery or during periods of reduced mobility.
  • Diagnostic Preparation: In some instances, it is used before medical imaging procedures, such as endoscopies or ultrasounds, to clear gas shadows and improve the visibility of internal organs.

Because the active ingredient is not absorbed into the bloodstream and acts locally within the digestive system, it is generally characterized by its mechanical rather than systemic mode of action.

Regulatory References

  1. Simethicone - StatPearls - NCBI Bookshelf
  2. FDA DailyMed Simethicone Labeling

What side effects are possible with Anaflat?

Possible Side Effects and Safety Information

The official safety profile for Anaflat (Simethicone) is shaped by its mechanism of action as a non-systemic antiflatulent; it is not absorbed into the bloodstream. This characteristic is why regulatory documents consistently cite a low incidence of side effects.


Adverse Reaction Scope

Adverse reactions are classified as uncommon or rare in regulatory texts. The documented effects fall primarily into two System-Organ Classes:

  • Gastrointestinal Disorders: Non-specific effects such as diarrhea, constipation, or nausea have been reported.
  • Immune System and Skin Disorders: The most clinically significant documented adverse reactions are rare hypersensitivity reactions, which include manifestations like pruritus (itching), rash, and edema (swelling).

Serious Adverse Reactions are specifically documented as severe forms of hypersensitivity, which in very rare instances may include anaphylaxis or severe respiratory difficulty.


Safety-Related Restrictions

Official regulatory labeling outlines specific limitations and contraindications for use:

  • Hypersensitivity: The medicine is restricted for use in individuals with known or suspected allergy to the active substance or any of its components.
  • Gastrointestinal Conditions: Use is contraindicated in patients with known or suspected gastrointestinal obstruction or perforation.

Due to the compound's chemical inertness and lack of systemic absorption, government safety documents state that no pharmacological drug interactions are expected with Anaflat.


Population-Specific Safety Notes

Official documents confirm the general suitability of Simethicone for the pediatric population, stating it presents no different safety concerns than in adults. It is also generally considered suitable for use during pregnancy and lactation due to its non-absorbed nature.

Overdose and Emergency Response

Overdose and When to Seek Help

This section summarizes the official regulatory information regarding Simethicone (Anaflat) overdose and mandated emergency actions.


Documented Overdose Profile and Actions

Simethicone is classified in official regulatory documents as an inert, non-systemic agent that is not absorbed into the bloodstream from the gastrointestinal tract. Consequently, the potential for systemic toxicity following oral overdose is considered low.

Overdose Component Official Regulatory Statement
Systemic Manifestations No reports of systemic toxicity are known or anticipated.
Local Manifestations Constipation is the only local effect noted as a potential outcome of excessive ingestion.
Specific Antidote No specific antidote is known or available.

Management, as described in regulatory labeling, is focused on symptomatic and supportive treatment, including discontinuation of the medication. The official instruction for a suspected overdose or the accidental ingestion of a large quantity is to seek immediate medical help or to contact a Poison Control Center immediately. Authorities also emphasize the need for professional consultation following high-dose ingestion in infants and children.

Therapeutic Uses of Anaflat

Main Uses of Anaflat

Anaflat is primarily used to relieve symptoms associated with the excessive accumulation of gas in the digestive tract. It is indicated for conditions where gas buildup causes physical discomfort or interferes with medical diagnostic procedures.

Relief of Gastrointestinal Gas

The medication is used to manage symptoms resulting from gastrointestinal gas, which may include:

  • Flatulence: The excessive expulsion of gas.
  • Meteorism: A condition characterized by abdominal distension and a sensation of tightness due to gas trapped in the intestines.
  • Aerophagia: Discomfort caused by the involuntary swallowing of air, often leading to bloating and belching.
  • Post-operative Gas: Relief of pressure and discomfort caused by gas accumulation following surgical procedures.

Support for Diagnostic Imaging

Beyond symptomatic relief, Anaflat serves a functional role in preparing the body for various diagnostic examinations of the abdominal area. By reducing the presence of gas bubbles and foam in the stomach and intestines, it helps provide a clearer view for medical professionals during:

  • Abdominal X-rays: Reducing gas shadows that can obscure internal organs.
  • Sonography (Ultrasound): Improving the transmission of sound waves for more accurate imaging.
  • Gastroscopy: Enhancing the visibility of the mucous membranes in the digestive tract.

Benefits and Mechanism

Anaflat acts locally within the digestive system. Its primary benefit is the physical breakdown of gas bubbles trapped in the stomach and intestinal contents. By changing the surface tension of these bubbles, the gas is released and can then be absorbed by the intestinal walls or eliminated naturally from the body. Because the active component is not absorbed into the bloodstream, its effects are concentrated entirely on providing mechanical relief within the gastrointestinal tract.

Eligibility and Restrictions for Use

Who Can and Cannot Use Anaflat?

Anaflat (Simethicone) eligibility is defined by official regulatory documents based on a limited set of absolute prohibitions, which reflects its non-systemic action.

Contraindications

Use is absolutely prohibited (contraindicated) for individuals with a known hypersensitivity or allergy to Simethicone or any components of the formulation. The medicine must also not be used if a patient has known or suspected Gastrointestinal (GI) Obstruction or Intestinal Perforation. These specific physical GI conditions prohibit use due to the potential for gas accumulation to complicate the patient's status.


Eligibility by Population

Anaflat is permitted for use across the entire age spectrum. Official labeling confirms eligibility for newborns and infants, as well as children, adolescents, and older adults. Use is also permitted during pregnancy and lactation (breastfeeding). Because the active substance is not systemically absorbed, the regulatory label specifies no restrictions or dosage adjustments are required for patients with hepatic impairment or renal impairment.

What should I know about interactions with other medicines?

The interaction profile for Anaflat (Simethicone) is shaped by its physical mode of action, which involves no systemic absorption. Consequently, official regulatory documents state that Anaflat does not engage in classical systemic drug-drug interactions, such as those involving metabolic enzymes or major drug transporters. No combinations are formally categorized as contraindicated in the official prescribing information.

The sole documented clinically significant interaction involves Levothyroxine (a thyroid hormone). This is classified as a non-systemic pharmacokinetic interference where co-administration may decrease the oral bioavailability of Levothyroxine. The official regulatory response to this reduction in exposure is a required timing separation.

Documented Interaction Constraints

Category Regulatory Statement
Interacting Medicine Levothyroxine (T4)
Interaction Outcome Decreases Levothyroxine oral bioavailability
Timing Rule Must be administered at least four hours apart from Levothyroxine
Food/Alcohol/Herbal No documented interactions with these substances

This timing rule represents the primary interaction-related restriction documented in regulatory guidance to ensure the expected therapeutic effectiveness of the thyroid hormone is maintained.

Mechanism of Action

Mechanism of Action: Physicochemical Modulation

Anaflat (Simethicone) acts through a physical, non-systemic mechanism targeting the contents of the digestive tract. The drug is a silicone polymer that is not absorbed into the body and does not engage with biological signaling pathways, allowing for a localized effect within the gut lumen. Its primary target is the gas-liquid interface of trapped gas bubbles. The molecule functions as an antifoaming agent by significantly reducing the surface tension of the bubble walls. This reduction destabilizes the frothy, high-surface-tension foam that typically holds gas captive. The resulting physiological effect is the coalescence (merging) of these numerous small bubbles into fewer, larger pockets of free gas.

Downstream Physiological Consequence

The creation of larger, free gas pockets modifies the physical state of the intestinal contents, allowing the body's natural peristalsis (muscle contractions) to propel the gas along the intestines. This mechanical action promotes the elimination of the gas through normal physiological processes such as belching or flatulence. In combination formulas, the mechanism may extend to enzymatic support, promoting the breakdown of undigested food substrates and thus limiting the material available for bacterial fermentation gas in the lower gut.

Dosage and Administration Information

Administration Method

Anaflat is typically available in oral formulations, such as drops or chewable tablets. The medication is intended for oral use and is often taken after meals or at bedtime to manage symptoms of gastrointestinal gas.

For liquid formulations, the bottle usually requires shaking before use to ensure the active ingredients are evenly distributed. When using drops, the liquid can be mixed with a small amount of water, juice, or infant formula if necessary.

General Usage Considerations

The effectiveness of the medication depends on consistent application according to the specific needs of the individual. Chewable tablets should be chewed thoroughly before swallowing to facilitate rapid action in the digestive tract.

It is important to maintain the integrity of the product by following the storage requirements listed on the packaging, generally keeping it in a cool, dry place away from direct sunlight. Ensuring the container is tightly closed after each use helps preserve the stability of the formulation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Anaflat

Evidence for Use in General Gastrointestinal Gas Relief

Research on Anaflat (Simethicone) was evaluated in studies exploring symptom change for common gas-related symptoms, such as abdominal pressure and bloating in adult populations. These research efforts explored how symptom intensity or variability changes over time. The available evidence includes randomized controlled trials (RCTs) and systematic reviews, which examined patient-reported experiences over relatively brief treatment periods. Studies monitored patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies, with measured changes being reported during the study period related to physical discomfort. Research describes changes measured during the study period when Simethicone was included in the intervention.

Evidence for Use in Diagnostic Medical Procedures

Simethicone was also evaluated as a preparation for certain diagnostic procedures, such as endoscopies and abdominal imaging. The purpose of research in this context was technical, focusing on the ingredient’s ability to reduce foam and small air bubbles. Systematic reviews and meta-analyses of trials were applied in studies examining procedural outcomes. The evidence was studied for Simethicone administration and examined outcomes like mucosal visibility scores during the procedures, with findings described in the research. The evidence base is generally consistent for its intended technical purpose but does not provide information regarding therapeutic symptom change.

Evidence in Special Populations

Research has explored Simethicone's use in several distinct populations. This includes studies relevant in trials assessing short-term symptom patterns in infants experiencing unexplained crying (colic). However, major scientific reviews describe that the findings were mixed, with many studies examining observed changes in crying time, which were frequently reported to be similar to placebo. Separately, observational data explored Simethicone's role in the management of post-operative abdominal distension, examining reported changes in distension shortly after certain surgical procedures.

Long-Term Research and Uncertainty

The majority of studies contributing to the evidence landscape applied in research exploring short-term symptom changes, resulting in limited follow-up durations. There is limited information for long-term outcomes, meaning that long-term effects are not fully established. Data for certain groups, such as individuals with functional gastrointestinal disorders or children older than infants, remain insufficient. The evidence quality varies across studies, and conflicting results in certain areas describe that certainty remains low for that research context.

Key Studies & References

  1. Simethicone - StatPearls - NCBI Bookshelf (NIH)
  2. Comparison of common interventions for the treatment of infantile colic: a systematic review of reviews and guidelines
  3. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia

Frequently Asked Questions (FAQ)

Common questions about Anaflat (FAQ)


Q: How quickly does Anaflat typically start to work?

Anaflat works through a physical mechanism that reduces the surface tension of gas bubbles in the gut. Since it is not absorbed into the body and acts directly on the contents of the digestive tract, relief is an individual experience, but effects are frequently reported to be observed shortly after administration, sometimes within an hour, according to general medical descriptions.


Q: How long do the effects of Anaflat usually last?

Because Anaflat is non-systemic, meaning it is not absorbed into the bloodstream, its effects are localized to the gas already trapped in the digestive tract. It is used 'as needed' (PRN) for symptoms, which reflects that the duration of relief can vary for each person depending on the ongoing production of new gas.


Q: Can Anaflat be used long-term?

Official guidance often describes Anaflat for the short-term, temporary relief of symptoms. In situations where an individual finds they need to take it regularly for longer than 14 days, public health guidance suggests consulting with a healthcare professional regarding the persistent nature of the symptoms.


Q: What are the most commonly reported side effects of Anaflat?

Anaflat is generally well tolerated, with documented adverse effects being uncommon or rare in official product information. The effects most frequently reported are minor and relate to the digestive system, such as loose stools, diarrhea, or nausea.


Q: Does taking Anaflat affect my ability to drive or operate machinery?

Official labeling does not list any warnings related to operating vehicles or machinery. Since Anaflat is not absorbed into the body and does not affect the brain or central nervous system, it is not expected to impair a person’s concentration or physical abilities.


Q: Does Anaflat cause weight gain or loss?

Regulatory safety information indicates that Anaflat is not expected to cause changes in body weight (gain or loss). The active ingredient works locally within the gut and does not enter the rest of the body to interact with metabolic or systemic processes.


Q: Is Anaflat considered a common drug or is it newly approved?

The active ingredient in Anaflat, Simethicone, is considered a well-established antiflatulent medicine. Official sources confirm it has been in use since the 1940s and is widely available over-the-counter.


Q: Is Anaflat available as a generic medicine?

Yes, Anaflat is a brand name. The active ingredient it contains, Simethicone, is widely available as a generic medicine and is often sold over-the-counter.


Q: What happens if I forget to take a dose of Anaflat?

Since Anaflat is generally taken as needed for symptoms, official guidance describes that if a dose is missed, and it is almost time for the next scheduled dose, the prior dose may be skipped, and the individual can return to the regular schedule without taking extra.


Q: Does Anaflat interact with common allergy medications?

Due to its non-systemic, physical mechanism of action, Anaflat does not engage in typical drug-drug interactions that involve metabolism. Official documents list no documented interactions with common allergy medications or most other oral medicines.


Q: Are there any dietary restrictions mentioned in the official Anaflat documents?

Official drug labeling explicitly states there are no known interactions between Anaflat and food or alcohol. Regulatory documents do not describe any drug-specific dietary restrictions, as there are no known interactions with food or alcohol.


Q: Are there any specific foods or drinks to avoid while using Anaflat?

Regulatory documents confirm there are no known interactions between Anaflat and food or beverages, meaning no specific foods or drinks are prohibited due to the medicine itself.


Q: Does Anaflat have any potential impact on sleep?

Anaflat does not affect the brain or central nervous system because it is not absorbed into the bloodstream. For this reason, official adverse reaction lists do not include sleep-related side effects such as drowsiness or insomnia.


Q: Is it possible to become dependent on Anaflat?

Official regulatory information confirms that the medicine is not associated with abuse, misuse, or the development of physical dependence. This is because its action is purely physical and local to the gut, meaning it does not affect brain chemistry or signaling pathways.


Q: Does Anaflat affect birth control pills?

Official interaction guidance states there is no known drug-drug interaction between Anaflat and hormonal contraceptives, including birth control pills. Its non-systemic mechanism means it does not affect the absorption or metabolism of the hormonal ingredients.


Q: Is Anaflat suitable for use by children or teenagers?

Yes, official documents confirm that Anaflat is permitted for use across the entire age spectrum, including children and adolescents. Its non-systemic action means it presents no different safety concerns in these groups than it does in adults.


Q: Do older adults (seniors) need to take a lower amount of Anaflat?

Official labeling states that because Anaflat is not systemically absorbed, no specific dosage adjustments are required for older adults. The standard adult dosage applies to those 12 years and older.


Q: Are there warnings about combining Anaflat with alcohol?

Official regulatory documents confirm there is no documented interaction or specific warning against combining Anaflat with alcohol. This is consistent with the fact that the medicine is not absorbed into the body.


Q: Is it normal to feel a bit tired when starting Anaflat?

Tiredness or fatigue is not listed as an adverse reaction in the official safety profile for Anaflat. The non-systemic nature of the drug means it does not interact with the central nervous system to cause sleepiness.


Q: How long after stopping Anaflat will it be completely out of my system?

Anaflat is not absorbed into the bloodstream and works entirely within the gut. Therefore, it is cleared from the body through normal bowel movements and is not considered to be 'in the system' in the same way that systemically absorbed drugs are.


Q: Can Anaflat cause changes in mood or behavior?

Due to its non-systemic mode of action, Anaflat does not affect the central nervous system. Official adverse reaction lists therefore do not include any reports of changes in mood or behavior.


Q: Does Anaflat require special monitoring or blood tests?

Anaflat does not require any special monitoring or routine blood tests. This reflects its non-systemic action, low incidence of side effects, and status as an over-the-counter product.


Q: Is Anaflat used to prevent symptoms, or only to treat them when they happen?

Regulatory guidance defines Anaflat for the 'symptomatic relief of excess gastrointestinal gas.' The drug is administered 'as needed' (PRN) for the presence of symptoms, which indicates its primary official use is for treating symptoms rather than long-term prevention.


Q: Are there any documented cases of overdose with Anaflat?

Regulatory-consistent information states that due to the non-absorbed nature of the drug, effects from an amount higher than recommended would likely be limited to common gastrointestinal upset, such as diarrhea or constipation.


Q: Are there any known side effects on hair or skin from Anaflat?

Official safety data lists rare hypersensitivity reactions that may include skin manifestations such as rash, itching, and swelling. There are no documented side effects specifically reported on hair in the official regulatory information.


Q: Is Anaflat safe for someone with high blood pressure?

Because Anaflat is not absorbed into the bloodstream, it does not have systemic effects and is not known to impact blood pressure or interfere with cardiovascular medications. No restrictions are listed based on high blood pressure in the official labeling.


Q: Does Anaflat have any known long-term safety concerns?

Due to its non-systemic mechanism, Anaflat's safety profile is consistent with low risk. While the majority of research has focused on short-term use, limiting long-term data, no specific long-term safety concerns are identified in regulatory documents.


Q: Can I stop taking Anaflat abruptly?

Yes, Anaflat can be stopped without a tapering schedule. Because it is used on an 'as needed' basis and does not cause physical dependence, there are no known withdrawal symptoms associated with stopping the medication.


Q: Are there any clinical trials currently running for Anaflat?

Clinical trial registries show that while many studies have been completed, new trials examining Simethicone (the active ingredient in Anaflat) are sometimes initiated. These studies often focus on technical applications, such as improving visibility during diagnostic procedures.


Q: Do official documents mention anything about driving restrictions while on Anaflat?

Official documents do not mention any specific driving restrictions while using Anaflat. This is consistent with its non-systemic action, which does not affect cognitive function.

How should Anaflat be stored and disposed of?

How to Store and Dispose of Anaflat

The storage and disposal requirements for Anaflat (Simethicone) are based strictly on official regulatory labeling to ensure product stability and safety.

Official Storage Conditions

  • Temperature: Store the product at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). Do not store the medicine in environments that expose it to freezing or excessive heat.
  • Protection: Keep the medicine protected from moisture and store liquid forms protected from light.
  • Container: The product must be kept in its original container, which should remain tightly closed when not in use.
  • Child Safety: All forms of the medicine must be stored out of the sight and reach of children.

Labeled Disposal Instructions

Disposal of unused or expired Anaflat should be done according to official guidelines, prioritizing drug take-back programs when available. Regulatory bodies instruct consumers not to dispose of the medicine via household wastewater, such as pouring it down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Anaflat found in:

A-Z Index: